Intrinsic value of Karyopharm Therapeutics - KPTI

Previous Close

$10.72

  Intrinsic Value

$0.54

stock screener

  Rating & Target

str. sell

-95%

Previous close

$10.72

 
Intrinsic value

$0.54

 
Up/down potential

-95%

 
Rating

str. sell

We calculate the intrinsic value of KPTI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  3
  4
  6
  9
  12
  17
  22
  29
  38
  48
  59
  73
  88
  104
  122
  142
  164
  187
  212
  239
  266
  296
  327
  359
  393
  428
  464
  502
  542
  583
Variable operating expenses, $m
  370
  571
  854
  1,240
  1,749
  2,405
  3,228
  4,238
  5,453
  6,888
  8,553
  10,457
  12,605
  14,997
  17,634
  20,512
  23,629
  26,977
  30,553
  34,351
  38,365
  42,593
  47,029
  51,673
  56,524
  61,582
  66,849
  72,330
  78,028
  83,951
Fixed operating expenses, $m
  93
  95
  97
  99
  101
  104
  106
  108
  111
  113
  116
  118
  121
  123
  126
  129
  132
  135
  138
  141
  144
  147
  150
  153
  157
  160
  164
  167
  171
  175
Total operating expenses, $m
  463
  666
  951
  1,339
  1,850
  2,509
  3,334
  4,346
  5,564
  7,001
  8,669
  10,575
  12,726
  15,120
  17,760
  20,641
  23,761
  27,112
  30,691
  34,492
  38,509
  42,740
  47,179
  51,826
  56,681
  61,742
  67,013
  72,497
  78,199
  84,126
Operating income, $m
  -460
  -662
  -946
  -1,330
  -1,838
  -2,492
  -3,311
  -4,317
  -5,526
  -6,953
  -8,610
  -10,503
  -12,638
  -15,016
  -17,638
  -20,499
  -23,596
  -26,925
  -30,479
  -34,253
  -38,243
  -42,444
  -46,853
  -51,468
  -56,288
  -61,314
  -66,549
  -71,995
  -77,657
  -83,543
EBITDA, $m
  -460
  -661
  -944
  -1,328
  -1,835
  -2,487
  -3,306
  -4,310
  -5,517
  -6,941
  -8,595
  -10,485
  -12,616
  -14,990
  -17,607
  -20,463
  -23,555
  -26,878
  -30,425
  -34,193
  -38,176
  -42,369
  -46,771
  -51,378
  -56,189
  -61,207
  -66,432
  -71,869
  -77,521
  -83,396
Interest expense (income), $m
  0
  0
  1
  3
  5
  9
  14
  20
  28
  38
  50
  63
  79
  98
  118
  141
  166
  194
  224
  256
  290
  327
  365
  406
  448
  493
  540
  588
  639
  691
  746
Earnings before tax, $m
  -460
  -663
  -948
  -1,336
  -1,848
  -2,506
  -3,332
  -4,345
  -5,564
  -7,003
  -8,673
  -10,582
  -12,735
  -15,135
  -17,779
  -20,665
  -23,790
  -27,149
  -30,735
  -34,543
  -38,570
  -42,809
  -47,258
  -51,916
  -56,781
  -61,854
  -67,137
  -72,633
  -78,348
  -84,288
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -460
  -663
  -948
  -1,336
  -1,848
  -2,506
  -3,332
  -4,345
  -5,564
  -7,003
  -8,673
  -10,582
  -12,735
  -15,135
  -17,779
  -20,665
  -23,790
  -27,149
  -30,735
  -34,543
  -38,570
  -42,809
  -47,258
  -51,916
  -56,781
  -61,854
  -67,137
  -72,633
  -78,348
  -84,288

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  107
  165
  247
  359
  506
  696
  934
  1,226
  1,578
  1,993
  2,475
  3,026
  3,647
  4,339
  5,102
  5,935
  6,837
  7,806
  8,841
  9,940
  11,101
  12,324
  13,608
  14,952
  16,355
  17,819
  19,343
  20,929
  22,578
  24,291
Adjusted assets (=assets-cash), $m
  107
  165
  247
  359
  506
  696
  934
  1,226
  1,578
  1,993
  2,475
  3,026
  3,647
  4,339
  5,102
  5,935
  6,837
  7,806
  8,841
  9,940
  11,101
  12,324
  13,608
  14,952
  16,355
  17,819
  19,343
  20,929
  22,578
  24,291
Revenue / Adjusted assets
  0.028
  0.024
  0.024
  0.025
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
  0.024
Average production assets, $m
  3
  5
  7
  11
  15
  21
  28
  37
  48
  60
  75
  91
  110
  131
  154
  179
  206
  235
  266
  299
  334
  371
  410
  450
  493
  537
  583
  630
  680
  732
Working capital, $m
  -62
  -95
  -142
  -207
  -292
  -401
  -538
  -706
  -909
  -1,148
  -1,426
  -1,743
  -2,101
  -2,500
  -2,939
  -3,419
  -3,938
  -4,497
  -5,093
  -5,726
  -6,395
  -7,099
  -7,839
  -8,613
  -9,421
  -10,264
  -11,142
  -12,056
  -13,006
  -13,993
Total debt, $m
  15
  51
  101
  169
  260
  376
  523
  702
  918
  1,173
  1,469
  1,807
  2,189
  2,614
  3,082
  3,593
  4,147
  4,742
  5,377
  6,052
  6,765
  7,516
  8,304
  9,130
  9,991
  10,890
  11,826
  12,799
  13,812
  14,864
Total liabilities, $m
  66
  102
  152
  220
  311
  427
  573
  753
  969
  1,224
  1,520
  1,858
  2,239
  2,664
  3,133
  3,644
  4,198
  4,793
  5,428
  6,103
  6,816
  7,567
  8,355
  9,180
  10,042
  10,941
  11,877
  12,850
  13,863
  14,915
Total equity, $m
  41
  64
  95
  138
  195
  269
  360
  473
  609
  769
  955
  1,168
  1,408
  1,675
  1,970
  2,291
  2,639
  3,013
  3,412
  3,837
  4,285
  4,757
  5,253
  5,771
  6,313
  6,878
  7,466
  8,078
  8,715
  9,376
Total liabilities and equity, $m
  107
  166
  247
  358
  506
  696
  933
  1,226
  1,578
  1,993
  2,475
  3,026
  3,647
  4,339
  5,103
  5,935
  6,837
  7,806
  8,840
  9,940
  11,101
  12,324
  13,608
  14,951
  16,355
  17,819
  19,343
  20,928
  22,578
  24,291
Debt-to-equity ratio
  0.360
  0.790
  1.060
  1.220
  1.330
  1.400
  1.450
  1.480
  1.510
  1.520
  1.540
  1.550
  1.550
  1.560
  1.560
  1.570
  1.570
  1.570
  1.580
  1.580
  1.580
  1.580
  1.580
  1.580
  1.580
  1.580
  1.580
  1.580
  1.580
  1.590
Adjusted equity ratio
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -460
  -663
  -948
  -1,336
  -1,848
  -2,506
  -3,332
  -4,345
  -5,564
  -7,003
  -8,673
  -10,582
  -12,735
  -15,135
  -17,779
  -20,665
  -23,790
  -27,149
  -30,735
  -34,543
  -38,570
  -42,809
  -47,258
  -51,916
  -56,781
  -61,854
  -67,137
  -72,633
  -78,348
  -84,288
Depreciation, amort., depletion, $m
  1
  1
  1
  2
  3
  4
  6
  7
  10
  12
  15
  18
  22
  26
  31
  36
  41
  47
  53
  60
  67
  74
  82
  90
  99
  107
  117
  126
  136
  146
Funds from operations, $m
  -460
  -662
  -947
  -1,334
  -1,844
  -2,501
  -3,326
  -4,338
  -5,555
  -6,991
  -8,658
  -10,564
  -12,713
  -15,108
  -17,748
  -20,630
  -23,749
  -27,102
  -30,681
  -34,484
  -38,503
  -42,735
  -47,177
  -51,826
  -56,682
  -61,746
  -67,020
  -72,507
  -78,212
  -84,142
Change in working capital, $m
  -23
  -34
  -47
  -64
  -85
  -109
  -137
  -168
  -203
  -239
  -278
  -317
  -358
  -399
  -440
  -480
  -519
  -558
  -596
  -633
  -669
  -705
  -739
  -774
  -809
  -843
  -878
  -913
  -950
  -987
Cash from operations, $m
  -436
  -629
  -900
  -1,269
  -1,760
  -2,392
  -3,189
  -4,169
  -5,352
  -6,752
  -8,380
  -10,247
  -12,356
  -14,710
  -17,308
  -20,150
  -23,230
  -26,543
  -30,085
  -33,851
  -37,834
  -42,030
  -46,437
  -51,052
  -55,874
  -60,903
  -66,142
  -71,594
  -77,262
  -83,155
Maintenance CAPEX, $m
  -1
  -1
  -1
  -1
  -2
  -3
  -4
  -6
  -7
  -10
  -12
  -15
  -18
  -22
  -26
  -31
  -36
  -41
  -47
  -53
  -60
  -67
  -74
  -82
  -90
  -99
  -107
  -117
  -126
  -136
New CAPEX, $m
  -1
  -2
  -2
  -3
  -4
  -6
  -7
  -9
  -11
  -13
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -37
  -39
  -40
  -42
  -44
  -46
  -48
  -50
  -52
Cash from investing activities, $m
  -2
  -3
  -3
  -4
  -6
  -9
  -11
  -15
  -18
  -23
  -27
  -32
  -37
  -43
  -49
  -56
  -63
  -70
  -78
  -86
  -95
  -104
  -113
  -122
  -132
  -143
  -153
  -165
  -176
  -188
Free cash flow, $m
  -438
  -631
  -903
  -1,274
  -1,766
  -2,401
  -3,200
  -4,184
  -5,370
  -6,774
  -8,407
  -10,278
  -12,393
  -14,752
  -17,358
  -20,206
  -23,293
  -26,614
  -30,164
  -33,937
  -37,928
  -42,134
  -46,550
  -51,174
  -56,006
  -61,046
  -66,295
  -71,758
  -77,438
  -83,342
Issuance/(repayment) of debt, $m
  15
  36
  50
  68
  90
  116
  146
  180
  216
  255
  296
  338
  381
  425
  468
  511
  554
  595
  635
  675
  713
  751
  788
  825
  862
  899
  936
  974
  1,012
  1,052
Issuance/(repurchase) of shares, $m
  470
  686
  980
  1,379
  1,904
  2,579
  3,423
  4,458
  5,700
  7,163
  8,859
  10,795
  12,975
  15,402
  18,073
  20,987
  24,138
  27,523
  31,134
  34,968
  39,018
  43,281
  47,754
  52,435
  57,323
  62,419
  67,725
  73,245
  78,985
  84,950
Cash from financing (excl. dividends), $m  
  485
  722
  1,030
  1,447
  1,994
  2,695
  3,569
  4,638
  5,916
  7,418
  9,155
  11,133
  13,356
  15,827
  18,541
  21,498
  24,692
  28,118
  31,769
  35,643
  39,731
  44,032
  48,542
  53,260
  58,185
  63,318
  68,661
  74,219
  79,997
  86,002
Total cash flow (excl. dividends), $m
  47
  91
  127
  173
  229
  294
  370
  454
  546
  644
  748
  855
  964
  1,074
  1,184
  1,293
  1,399
  1,504
  1,606
  1,705
  1,803
  1,898
  1,992
  2,085
  2,178
  2,271
  2,365
  2,461
  2,559
  2,660
Retained Cash Flow (-), $m
  -470
  -686
  -980
  -1,379
  -1,904
  -2,579
  -3,423
  -4,458
  -5,700
  -7,163
  -8,859
  -10,795
  -12,975
  -15,402
  -18,073
  -20,987
  -24,138
  -27,523
  -31,134
  -34,968
  -39,018
  -43,281
  -47,754
  -52,435
  -57,323
  -62,419
  -67,725
  -73,245
  -78,985
  -84,950
Prev. year cash balance distribution, $m
  97
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -325
  -595
  -853
  -1,206
  -1,676
  -2,284
  -3,054
  -4,004
  -5,154
  -6,519
  -8,111
  -9,940
  -12,011
  -14,327
  -16,889
  -19,694
  -22,739
  -26,019
  -29,528
  -33,262
  -37,215
  -41,383
  -45,762
  -50,349
  -55,144
  -60,147
  -65,360
  -70,784
  -76,426
  -82,290
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -312
  -545
  -742
  -993
  -1,299
  -1,658
  -2,063
  -2,503
  -2,961
  -3,418
  -3,852
  -4,242
  -4,567
  -4,810
  -4,958
  -5,005
  -4,948
  -4,792
  -4,547
  -4,227
  -3,849
  -3,434
  -2,999
  -2,564
  -2,145
  -1,755
  -1,403
  -1,095
  -834
  -620
Current shareholders' claim on cash, %
  25.4
  5.9
  1.4
  0.4
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

FINANCIAL RATIOS  of  Karyopharm Therapeutics (KPTI)

Valuation Ratios
P/E Ratio -4.1
Price to Sales 0
Price to Book 2.8
Price to Tangible Book
Price to Cash Flow -5.3
Price to Free Cash Flow -5.3
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -100%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -55.7%
Ret/ On Assets - 3 Yr. Avg. -50.1%
Return On Total Capital -61.1%
Ret/ On T. Cap. - 3 Yr. Avg. -53.8%
Return On Equity -61.1%
Return On Equity - 3 Yr. Avg. -53.8%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate -0.9%
Eff/ Tax Rate - 3 Yr. Avg. -0.3%
Payout Ratio 0%

KPTI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the KPTI stock intrinsic value calculation we used $1.605 million for the last fiscal year's total revenue generated by Karyopharm Therapeutics. The default revenue input number comes from 0001 income statement of Karyopharm Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our KPTI stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for KPTI is calculated based on our internal credit rating of Karyopharm Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Karyopharm Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of KPTI stock the variable cost ratio is equal to 14400%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $91 million in the base year in the intrinsic value calculation for KPTI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Karyopharm Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Karyopharm Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the KPTI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for KPTI are equal to 125.5%.

Life of production assets of 3.5 years is the average useful life of capital assets used in Karyopharm Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for KPTI is equal to -2400.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $129.464 million for Karyopharm Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 60.375 million for Karyopharm Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Karyopharm Therapeutics at the current share price and the inputted number of shares is $0.6 billion.

RELATED COMPANIES Price Int.Val. Rating
STML Stemline Thera 12.31 0.39  str.sell
SGEN Seattle Geneti 54.98 1.07  str.sell
CELG Celgene 71.02 340.31  str.buy
MRK Merck&Co 74.69 33.05  str.sell
ABBV AbbVie 89.69 174.70  str.buy
AGIO Agios Pharmace 64.15 1.63  str.sell
JNJ Johnson&Johnso 145.62 176.79  buy
BMY Bristol-Myers 52.85 71.64  hold

COMPANY NEWS

▶ Karyopharm Therapeutics: 3Q Earnings Snapshot   [07:34AM  Associated Press]
▶ Karyopharm Therapeutics Announces Management Change   [Oct-26-18 07:00AM  GlobeNewswire]
▶ Karyopharm to Participate in Upcoming Investor Conferences   [Sep-25-18 07:00AM  GlobeNewswire]
▶ Karyopharm Therapeutics Ramps Up Hiring Ahead of Potential FDA Approval   [Aug-24-18 05:16PM  The Wall Street Journal]
▶ [$$] Papa John's and 3 Other Small-Cap Value Plays   [Aug-07-18 01:27PM  Barrons.com]
▶ Karyopharm Therapeutics: 2Q Earnings Snapshot   [07:30AM  Associated Press]
▶ Karyopharm to Participate in Upcoming Investor Conferences   [Aug-02-18 07:00AM  GlobeNewswire]
▶ Karyopharm to Participate in Upcoming Investor Conferences   [May-31-18 07:00AM  GlobeNewswire]
▶ Karyopharm Therapeutics: 1Q Earnings Snapshot   [May-10-18 07:59AM  Associated Press]
▶ Newtons Karyopharm to seek FDA approval for cancer drug after trial win   [Apr-30-18 07:14PM  American City Business Journals]
▶ Benzinga Pro's 5 Stocks To Watch Today   [Apr-10-18 08:42AM  Benzinga]
▶ Karyopharm Therapeutics posts 4Q loss   [07:27AM  Associated Press]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Feb-10-18 10:33AM  Motley Fool]
▶ Karyopharm to Participate in Upcoming Investor Conferences   [Feb-07-18 07:00AM  GlobeNewswire]
▶ Biotechnology Movers: Karyopharm And Synergy   [Jan-26-18 08:42AM  Market Exclusive]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.